Hinova Announces First Patient Dosed in a Phase I Clinical Trial of HP518, an Orally Bioavailable Chimeric Degrader Targeting Androgen Receptor for Prostate Cancer Treatment
- Written by PR Newswire
MELBOURNE, Australia, Jan. 20, 2022 /PRNewswire/ -- Hinova Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused on developing novel therapeutics for cancers and metabolic diseases through targeted protein degradation technologies, today announced that the first patient with metastatic castration-resistant prostate cancer...
